Physician profile
Abigail Harada
NPI 1306041967
$7,996.30
in general payments reported to CMS, 2019-2025
30 companies · $4,530 in 2025
The $4,530 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $109 · 2021: $346 · 2022: $580 · 2023: $744 · 2024: $1,386 · 2025: $4,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,357 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,356.67 |
| Education | $302.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,354.90 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,132.76 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $956.78 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $797.81 | 2023-2025 | |
| Leo Pharma INC. | $693.54 | 2023-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $651.47 | 2021-2025 | Xolair |
| Galderma Laboratories, L.P. | $338.20 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $288.97 | 2024-2025 | Ebglyss, Taltz |
| Csl Behring | $265.00 | 2024-2025 | Andembry, Hizentra |
| Ars Pharmaceuticals Operations, INC. | $231.91 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $199.94 | 2025 | |
| Biocryst US Sales Co., LLC | $111.75 | 2024-2025 | Orladeyo |
| Blueprint Medicines Corporation | $107.68 | 2024-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $106.75 | 2024-2025 | Cuvitru, Takhzyro |
| Ionis Pharmaceuticals, INC. | $95.86 | 2025 | Dawnzera |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $75.64 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $74.34 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.92 | 2024 | Spiriva Respimat |
| Cycle Pharmaceuticals INC | $55.31 | 2025 | Sajazir |
| Greer Laboratories, INC. | $53.80 | 2025 | Oralair |
| Verona Pharma, INC. | $49.38 | 2025 | Ohtuvayre |
| Bausch & Lomb Americas INC. | $46.20 | 2025 | Miebo |
| Insmed, INC. | $34.56 | 2025 | Brinsupri, Arikayce |
| Abbvie INC. | $31.39 | 2025 | |
| Organon LLC | $31.02 | 2025 | |
| Pfizer INC. | $30.95 | 2024 | |
| Amgen INC. | $29.24 | 2025 | Actimmune |
| Pharming Healthcare, INC. | $28.45 | 2025 | Ruconest |
| Arcutis Biotherapeutics, INC. | $28.42 | 2024 | Zoryve |
| Regeneron Pharmaceuticals, INC. | $28.36 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Harada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.